The Medical Letter on Drugs and Therapeutics
Drugs for Type 2 Diabetes
The full article is available to subscribers Subscriber Login   
Revised 5/17/18: Information on newly approved drugs, recently published clinical trials, and cardiovascular outcomes have been changed.

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of <7%.1 Treating to this target has been shown to prevent microvascular complications (retinopathy, nephropathy, and neuro pathy), but whether it prevents macrovascular outcomes is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease, a history of severe hypoglycemia, diabetes-related complications or comorbidities, or a long duration of disease.2,3

LIFESTYLE MODIFICATIONS — Diet, exercise, and weight loss can improve glycemic control and are recommended for all patients, but most patients with type 2 diabetes ultimately require drug therapy. In a 10-year randomized controlled trial in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Type 2 Diabetes
Article code: 1512a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian